Recently, Shanghai Escugen Biotechnology Co., Ltd. (hereinafter referred to as "Escugen") and Shanghai GFK Pharmaceutical Engineering Technology Co., Ltd. (hereinafter referred to as "GFK") officially signed a cooperation agreement. Under the agreement, GFK will leverage its independently developed AI Bio-Big Data Intelligent Platform to provide Escugen with accurate and efficient target discovery services, helping Escugen expand the boundaries of innovative R&D. In turn, Escugen will give full play to its strengths in innovative drug R&D to accelerate the new drug development process.